Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531
- 31 May 2024
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (8) , e31089
Abstract
Background: We previously reported excellent three‐year overall survival (OS) for patients with newly diagnosed intermediate‐risk neuroblastoma treated with a biology‐ and response‐based algorithm on the Children's Oncology Group study ANBL0531. We now present the long‐term follow‐up results. Methods: All patients who met the age, stage, and tumor biology criteria for intermediate‐risk neuroblastoma were eligible. Treatment was based on prognostic biomarkers and overall response. Event‐free survival (EFS) and OS were estimated by the Kaplan‐Meier method. Results: The 10‐year EFS and OS for the entire study cohort ( n = 404) were 82.0% (95% confidence interval (CI), 77.2%‐86.9%) and 94.7% (95% CI, 91.8%‐97.5%), respectively. International Neuroblastoma Staging System stage 4 patients ( n = 133) had inferior OS compared with non–stage 4 patients ( n = 271; 10‐year OS: 90.8% [95% CI, 84.5%‐97.0%] vs 96.6% [95% CI, 93.9%‐99.4%], p = .02). Infants with stage 4 tumors with ≥1 unfavorable biological feature ( n = 47) had inferior EFS compared with those with favorable biology ( n = 61; 10‐year EFS: 66.8% [95% CI, 50.4%‐83.3%] vs 86.9% [95% CI, 76.0%‐97.8%], p = .02); OS did not differ (10‐year OS: 84.4% [95% CI, 71.8%‐97.0%] vs 95.0% [95% CI, 87.7%‐100.0%], p = .08). Inferior EFS but not OS was observed among patients with tumors with ( n = 26) versus without ( n = 314) 11q loss of heterozygosity (10‐year EFS: 68.4% [95% CI, 44.5%‐92.2%] vs 83.9% [95% CI, 78.7%‐89.2%], p = .03; 10‐year OS: 88.0% [95% CI, 72.0%‐100.0%] vs 95.7% [95% CI, 92.8%‐98.6%], p = .09). Conclusions: The ANBL0531 trial treatment algorithm resulted in excellent long‐term survival. More effective treatments are needed for subsets of patients with unfavorable biology tumors.Keywords
Funding Information
- St. Baldrick's Foundation
- National Cancer Institute (R35 CA220500)
This publication has 27 references indexed in Scilit:
- Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectPediatric Blood & Cancer, 2022
- Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectPediatric Blood & Cancer, 2022
- Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)European Journal of Cancer, 2019
- NeuroblastomaNature Reviews Disease Primers, 2016
- Relapsed neuroblastomas show frequent RAS-MAPK pathway mutationsNature Genetics, 2015
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in NeuroblastomaCancer Cell, 2014
- Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)British Journal of Cancer, 2011
- The International Neuroblastoma Pathology Classification (the Shimada system)Cancer, 1999
- Prognostic factors in Neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosisCancer, 1988
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977